Characterization and Diagnostic Applications of Patient-derived Tumor Organoids

Title: Characterization and Diagnostic Applications of Patient-derived Tumor Organoids 3D CELL CULTURE SUMMIT MASTER SERIES As part of the Englander Institute for Precision Medicine, the Tumor Organoid Platform is an active program focused on development of 3D patient derived tumor organoids (PDTO) from metastatic and primary anatomic sites, obtained through biopsies, surgical resections and rapid autopsy procedures. In this setting, the Tumor Organoid Platform has established a “living biobank” of 160 patient tumor organoids comprising 14 different tumor types. These models are used for High Throughput Drug Screening, the identification of new targets using CRISPR Cas9 Screenings and the generation of co-cultures with different cell types present in the tumor microenvironment, including immune cells and fibroblasts.